Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

Children with congenital heart disease and ADHD can benefit from stimulant medications

A new study finds that children with congenital heart disease and ADHD can take stimulant medications without fear of significant cardiovascular side effects.

5 Oct 2015

Yale ResearchKit app can help assess heart problems in children and young adults

Imagine being able to contribute to research about heart problems affecting children and adults with an iPhone app. That idea is now a reality with today's launch of the Yale Cardiomyopathy Index, an iPhone-based clinical study to better understand quality of life for people ages two to 80 who have or may develop a cardiomyopathy -- an abnormality in the heart muscle.

1 Oct 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Sticky, protein-rich gel improves cardiac function after simulated heart attacks

A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and restore their metabolism after transplantation, improving cardiac function after simulated heart attacks, according to results of a new study.

25 Sep 2015

Study challenges new ESC Guidelines to identify high-risk HCM patients who need ICDs for prevention of sudden death

Hypertrophic cardiomyopathy (HCM), a genetic form of heart disease with thick heart walls, is the most common cause of sudden death in patients under 50. While only a minority of patients with HCM are at risk, the implantable cardioverter-defibrillator (ICD) can effectively prevent sudden death in those patients.

22 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

Surgeons participate in record-setting day of organ transplantation at Baylor University Medical Center

One week ago, surgical teams took part in a record-setting day of organ transplantation at Baylor University Medical Center at Dallas. Surgeons on the medical staff performed nine organ transplants on seven patients in one calendar day.

11 Sep 2015

European cardiomyopathies registry shows higher than expected use of defibrillators, genetic testing

The most representative snapshot of real world practice in cardiomyopathies in Europe has shown a higher than expected use of defibrillators and genetic testing. The baseline results of the ESC's EORP Cardiomyopathy Registry Pilot are presented for the first time today at ESC Congress 2015.

2 Sep 2015

Defibrillator does not improve outcomes in patients with CRT pacemaker

Most patients with a cardiac resynchronisation therapy (CRT) pacemaker would not benefit from the addition of a defibrillator, according to results from the CeRtiTuDe cohort study presented for the first time today at ESC Congress1 and published in European Heart Journal.

1 Sep 2015

BCM injection does not prevent cardiac remodeling in heart attack patients

An investigational material known Bioabsorbable Cardiac Matrix (BCM) that is injected through the coronary artery to prevent cardiac remodelling in heart attack patients had no significant effect compared to a saline placebo, according to results of the PRESERVATION I trial.

1 Sep 2015

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

A 40 to 80 day treatment with the antiparasitic medication benznidazole significantly reduced parasite activity in the blood, but not progression, of serious heart problems over a 5-year period among patients with established Chagas disease (CD) cardiomyopathy, results of the BENEFIT trial show.

1 Sep 2015

Only 1 in 10 heart failure patients referred to cardiac rehabilitation program after hospitalization

Only 1 in 10 heart failure patients is referred to a cardiac rehabilitation program after being hospitalized, despite strong evidence that such exercise programs improve quality of life and reduce the likelihood of future hospitalizations.

19 Aug 2015

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.

3 Aug 2015

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.

30 Jul 2015

No significant research undertaken to prevent or treat PPCM in healthy pregnant women, study reveals

Peripartum cardiomyopathy (PPCM) is a rare disorder characterized by weakened pumping of the heart, or "left ventricular dysfunction," which results in otherwise healthy pregnant women experiencing heart failure shortly before or up to five months after they deliver healthy babies. Despite the seriousness of this condition, a new study published in the Canadian Journal of Cardiology revealed that no significant research has been undertaken to explore how to prevent or treat this disorder.

16 Jul 2015

Isis Pharmaceuticals receives $2.15 million milestone payment to advance ISIS-SMN Rx study in children with SMA

Isis Pharmaceuticals, Inc. announced today that it has earned a $2.15 million milestone payment from Biogen related to advancing the ongoing pivotal Phase 3 study (CHERISH) evaluating ISIS-SMN Rx in children with spinal muscular atrophy (SMA).

14 Jul 2015

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).

6 Jul 2015

UVA Health System opens high-tech clinical genomics lab

The University of Virginia Health System has opened a high-tech clinical genomics lab that will personalize care for patients, help doctors determine the best treatments for cancers and other diseases, and allow UVA to offer the most cutting-edge clinical trials.

1 Jul 2015

Sugar-gobbling enzyme helps restore normal function in heart muscles of diabetic rats

Working with heart muscle cells from diabetic rats, scientists at Johns Hopkins have located what they say is the epicenter of mischief wreaked by too much blood sugar and used a sugar-gobbling enzyme to restore normal function in the glucose-damaged cells of animal heart muscles.

25 Jun 2015

Cardiomyopathy News and Research

Further Reading

Children with congenital heart disease and ADHD can benefit from stimulant medications

Yale ResearchKit app can help assess heart problems in children and young adults

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Sticky, protein-rich gel improves cardiac function after simulated heart attacks

Study challenges new ESC Guidelines to identify high-risk HCM patients who need ICDs for prevention of sudden death

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Surgeons participate in record-setting day of organ transplantation at Baylor University Medical Center

European cardiomyopathies registry shows higher than expected use of defibrillators, genetic testing

Defibrillator does not improve outcomes in patients with CRT pacemaker

BCM injection does not prevent cardiac remodeling in heart attack patients

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

Only 1 in 10 heart failure patients referred to cardiac rehabilitation program after hospitalization

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

No significant research undertaken to prevent or treat PPCM in healthy pregnant women, study reveals

Isis Pharmaceuticals receives $2.15 million milestone payment to advance ISIS-SMN Rx study in children with SMA

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

UVA Health System opens high-tech clinical genomics lab

Sugar-gobbling enzyme helps restore normal function in heart muscles of diabetic rats

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News